Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Business Wire•04/11/2026•08:00 ET
0
Key Highlights
- ➤EB-003 modulated prefrontal and parietal cortical brain-wave oscillations in mice
- ➤EB-003 produced a neurophysiological profile differentiated from DMT
- ➤DMT induced epileptic-like EEG activity and acute body spasms
- ➤EB-003 did not induce abnormal epileptiform activity or disruptive sedation patterns
- ➤qEEG findings support pharmacodynamic biomarker use in planned Phase 1 trials
Expert Statements
Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric Biosciences
“These results demonstrate EB-003 induces measurable activity in relevant brain regions with a profile differentiated from DMT, providing additional evidence of EB-003’s unique pharmacological profile and mechanism of action.”
Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric Biosciences
“The research has also identified qEEG as a suitable objective biomarker that we can utilize in upcoming human studies.”
Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric Biosciences
“As we advance toward our planned Phase 1 clinical trial of EB-003, the ability to correlate drug exposure to changes in brain activity on qEEG could help us identify biologically active doses and make more informed decisions for subsequent trials.”
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT
Get started
Create a free account to read the full story.